Pharmaceutical application of 15- or 16-substituted testosterone analogues
First Claim
1. A pharmaceutical oral dosage unit containing at least 10 μ
- g of an estrogen and at least 10 μ
g of a steroid selected from the group consisting of 15-hydroxytestosterones, precursors thereof, mixtures thereof and precursors of said mixtures; and
a pharmaceutically acceptable excipient, wherein said oral dosage unit is selected from the group consisting of a tablet, a capsule and a chachet, wherein the precursors of the hydroxytestosterones are derivatives of the hydroxytestosterones wherein a hydrogen atom of at least one hydroxyl group has been substituted by an acyl radical of a hydrocarbon carboxylic, sulfonic or sulfamic acid of 1-25 carbon atoms;
tetrahydrofuranyl;
tetrahydropyranal;
or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, and wherein the pharmaceutical oral dosage unit is orally active.
2 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to pharmaceutical dosage units for oral, transmucosal or transdermal administration containing 15- or 16-substituted testosterone analogues, as well as to therapeutic methods that employ these testosterone analogues. More particularly, the invention is concerned with such pharmaceutical dosage units containing at least 10 μg of an androgenic steroid selected from the group consisting of 15-hydroxytestosterones, 16-hydroxytestosterones, precursors thereof and mixtures of these hydroxytestosterones and/or their precursors; and a pharmaceutically acceptable excipient. The term “15-hydroxytestosterones” encompasses both 15α-hydroxytestosterone (15α, 17β-dihydroxy-4-androsten-3-one) and 15β-hydroxytestosterone (15β, 17β-dihydroxy-4-androsten-3-one). Similarly, the term “16-hydroxytestosterones” encompasses both 16α-hydroxytestosterone hydroxytestosterone (16α, 17β-dihydroxy-4-androsten-3-one) and 16β-hydroxytestosterone (16β, 17β-dihydroxy-4-androsten-3-one). The androgenic steroids according to the invention are advantageously employed in e.g. a method of treating or preventing androgen deficiency or a method of hormonal contraception.
61 Citations
10 Claims
-
1. A pharmaceutical oral dosage unit containing at least 10 μ
- g of an estrogen and at least 10 μ
g of a steroid selected from the group consisting of 15-hydroxytestosterones, precursors thereof, mixtures thereof and precursors of said mixtures; and
a pharmaceutically acceptable excipient, wherein said oral dosage unit is selected from the group consisting of a tablet, a capsule and a chachet, wherein the precursors of the hydroxytestosterones are derivatives of the hydroxytestosterones wherein a hydrogen atom of at least one hydroxyl group has been substituted by an acyl radical of a hydrocarbon carboxylic, sulfonic or sulfamic acid of 1-25 carbon atoms;
tetrahydrofuranyl;
tetrahydropyranal;
or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue, and wherein the pharmaceutical oral dosage unit is orally active. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
- g of an estrogen and at least 10 μ
Specification